Mitotic inhibitors include- Etoposide, Vincristine, Vinblastine, Teniposide, Vinorelbine tartarate

Drug interaction- summary

Sodium salicylate / Sulfamethizole /  Tolbutamide  +   Tenoposide 

Mitotic inhibitors include- Etoposide, Vincristine, Vinblastine, Teniposide, Vinorelbine tartarate 

Myelosuppression 75%          GI Mucositis 76%          nausea/vomiting 29%

Dermatologic     Alopecia 9% rash 3% Cardiovascular Hypotension 2%

                           Miscellaneous Fever 3%    Infection 12%      Bleeding 5%

Approved by FDA on July 14, 1992

Teniposide in combination with other approved anticancer agents for induction therapy in patients with refractory childhood lymphoblastic leukemia ( ALL )

Dosage:

Teniposide must be administered by IV infusion. Administer over 30 to 60 minutes or longer. Do not give by rapid IV injection. Hypotension has been reported following rapid IV administration.

1. Contraceptive measures are recommended during treatment

2. Notify physician, if fever, chills, rapid heart beat, difficult breathing occurs

Pregnancy -  Avoid becoming pregnant

Lactation-  because of potential for serious adverse reactions in nursing infants,             decide whether to discontinue nursing or the drug depending on importance                            of the drug to the mother

Children- Tenoposide is indicated for use in children